SAB Biotherapeutics (SABS) Research & Development (2021 - 2026)
SAB Biotherapeutics' (SABS) quarterly Research & Development came in at $13.4 million in Q1 2026, up 74.97% YoY from $7.7 million in Q1 2025, and up 24.88% on a QoQ basis from $10.7 million in Q4 2025.
SAB Biotherapeutics (SABS) Research & Development (2021 - 2026) Analysis & Trends
SAB Biotherapeutics (SABS) has 6 years of Research & Development data on file, last reported at $13.4 million in Q1 2026.
- Quarterly Research & Development rose 74.97% year-over-year to $13.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.1 million (up 33.81% YoY) and the FY2025 annual result came in at $34.4 million, up 13.56% from the prior year.
- Research & Development climbed to $13.4 million in Q1 2026, from $10.7 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $13.4 million in Q1 2026 to a low of $3.7 million in Q2 2023.
- A 5-year average of $7.7 million and a median of $7.7 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development plunged 65.96% — and 2024, when it jumped 94.81%.
- Tracing SABS's Research & Development over 5 years: stood at $7.1 million in 2022, then tumbled by 39.8% to $4.3 million in 2023, then jumped by 78.05% to $7.7 million in 2024, then surged by 40.21% to $10.7 million in 2025, then rose by 24.88% to $13.4 million in 2026.
- The last three Research & Development figures came in at $13.4 million (Q1 2026), $10.7 million (Q4 2025), and $9.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | SAB Biotherapeutics | 308.92 Mn | 308.92 Mn | - | 16.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.17 Mn |
| Mar 31, 2026 | 13.40 Mn |
| Dec 31, 2025 | 10.73 Mn |
| Sep 30, 2025 | 8.97 Mn |
| Jun 30, 2025 | 7.00 Mn |
| Mar 31, 2025 | 7.66 Mn |
| Dec 31, 2024 | 7.65 Mn |
| Sep 30, 2024 | 7.83 Mn |
| Jun 30, 2024 | 6.82 Mn |
| Mar 31, 2024 | 8.15 Mn |
| Dec 31, 2023 | 4.30 Mn |
| Sep 30, 2023 | 4.02 Mn |
| Jun 30, 2023 | 3.66 Mn |
| Mar 31, 2023 | 4.54 Mn |
| Dec 31, 2022 | 7.14 Mn |
| Sep 30, 2022 | 7.35 Mn |
| Jun 30, 2022 | 8.58 Mn |
| Mar 31, 2022 | 13.32 Mn |
| Dec 31, 2021 | 10.65 Mn |
| Sep 30, 2021 | 15.07 Mn |